H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle

BMC Cell Biology

Volumn 14, Issue 1, 2013, Pages

  Sun, Ye ^a   Su, Li ^b   Wang, Zhongxiao ^b   Xu, Yi ^b   Xu, Xun ^b  

^a SHANGHAI INSTITUTE OF TECHNOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cornea; H RN; HUVECs; Neovascularization; Peptide

Indexed keywords

ARGINYLASPARAGINYLPROPYLARGINYLGLYCYLGLUTAMYLGLUTAMYLGLYCYLGLYCYLPROPYLTRYPTOPHAN; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL MOVEMENT; COLLAGEN; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; G1 PHASE CELL CYCLE CHECKPOINTS; HEPATOCYTE GROWTH FACTOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LAMININ; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874059886     PISSN: None     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-14-8     Document Type: Article

References (31)

1. Biswas PS, Rouse BT. Early events in HSV keratitis-setting the stage for a blinding disease. Microbes Infect. 2005, 7:799-810. 10.1016/j.micinf.2005.03.003, 15857807.
2. Bock F, Konig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C. Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 2007, 104:336-344. 10.1007/s00347-007-1512-2, 17372736.
3. Scorcia V, Busin M. Survival of mushroom keratoplasty performed in corneas with postinfectious vascularized scars. Am J Ophthalmol 2012, 153:44-50. 10.1016/j.ajo.2011.05.020, 21851921.
4. Li N, Wang X, Wan P, Huang M, Wu Z, Liang X, Liu Y, Ge J, Huang J, Wang Z. Tectonic lamellar keratoplasty with acellular corneal stroma in high-risk corneal transplantation. Mol Vis 2011, 17:1909-1917. 3154122, 21850165.
5. Han ES, Wee WR, Lee JH, Kim MK. Long-term outcome and prognostic factor analysis for keratolimbal allografts. Graefes Arch Clin Exp Ophthalmol 2011, 249:1697-1704. 10.1007/s00417-011-1760-3, 21837442.
6. Sennlaub F, Courtois Y, Goureau O. Nitric oxide synthase-II is expressed in severe corneal alkali burns and inhibits neovascularization. Invest Ophthalmol Vis Sci. 1999, 40:2773-2779.
7. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998, 43:245-269. 10.1016/S0039-6257(98)00035-6, 9862312.
8. Regenfuss B, Bock F, Parthasarathy A, Cursiefen C. Corneal (lymph)angiogenesis-from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 2008, 6:191-201. 10.1089/lrb.2008.6348, 19093792.
9. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R, Pavan-Langston D, Dana R. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009, 127:381-389. 10.1001/archophthalmol.2009.18, 2703579, 19365012.
10. Holzer MP, Solomon KD, Vroman DT, Sandoval HP, Margaron P, Kasper TJ, Crosson CE. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci. 2003, 44:2954-2958. 10.1167/iovs.02-0572, 12824237.
11. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005, 293:1509-1513. 10.1001/jama.293.12.1509, 15784876.
12. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. N Engl J Med 2004, 351:2805-2816. 10.1056/NEJMoa042760, 15625332.
13. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 2006, 17:1399-1403. 10.1093/annonc/mdl161, 16873427.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
15. Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 2007, 13:2074-2086. 10.2174/138161207781039715, 17627540.
16. Xu Y, Zhao H, Zheng Y, Gu Q, Ma J, Xu X. A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Mol Vis 2010, 16:1982-1995. 2956696, 21031024.
17. Zhou SY, Xie ZL, Xiao O, Yang XR, Heng BC, Sato Y. Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1. Mol Vis 2010, 16:1389-1398. 2913137, 20680097.
18. Mutan VR, Auerbach R. Angiogenesis in the mouse cornea. Science 1979, 205:1418-1419. 10.1126/science.472761, 472761.
19. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996, 37:1625-1632.
20. Li T, Hu A, Li S, Luo Y, Huang J, Yu H, Ma W, Pan J, Zhong Q, Yang J, Wu J, Tang S. KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment forcorneal neovascularization. Mol Vis 2011, 17:797-803. 3081801, 21528000.
21. Prager GW, Mihaly J, Brunner PM, Koshelnick Y, Hoyer-Hansen G, Binder BR. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 2009, 113:1383-1390. 10.1182/blood-2008-06-164210, 18948573.
22. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998, 273:13313-13316. 10.1074/jbc.273.21.13313, 9582377.
23. Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci. 2002, 59:126-142. 10.1007/s00018-002-8410-1, 11846025.
24. Mani S, Wang C, Wu K, Francis R, Pestell R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs. 2000, 9:1849-1870. 10.1517/13543784.9.8.1849, 11060782.
25. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006, 70:146-157. 10.1016/j.cardiores.2006.01.015, 16515776.
26. Yu WZ, Zou H, Li XX, Yan Z, Dong JQ. Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization. Ophthalmic Res. 2008, 40:19-25. 10.1159/000111154, 18025837.
27. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, Ge R. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 2005, 280:27935-27948. 10.1074/jbc.M414320200, 15923192.
28. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62:625-631.
29. Li J, Chen X, Xiao W, Ma W, Li T, Huang J, Liu X, Liang X, Tang S, Luo Y. Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells. Biochem Biophys Res Commun 2011, 404:349-356. 10.1016/j.bbrc.2010.11.122, 21134355.
30. Chen JY, Hwang CC, Chen WY, Lee JC, Fu TF, Fang K, Chu YC, Huang YL, Lin JC, Tsai WH, Chang HW, Chen BH, Chiu CC. Additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells. Life Sci 2010, 87:350-357. 10.1016/j.lfs.2010.06.017, 20624405.
31. Przygodzka P, Boncela J, Cierniewski CS. Matrin 3 as a key regulator of endothelial cell survival. Exp Cell Res. 2011, 317:802-811. 10.1016/j.yexcr.2010.12.009, 21182838.